Chemomab Therapeutics announced its Q1 2026 financial results and presented new clinical data showing nebokitug's promising effects in treating primary sclerosing cholangitis (PSC) and co-existing inflammatory bowel disease (IBD). The data revealed nebokitug's ability to modulate key disease pathways and inflammatory markers, potentially making it the first FDA-approved disease-modifying treatment for PSC. The company continues to explore partnering options and plans a Phase 3 trial based on positive Phase 2 results. Financially, Chemomab reported a net loss of $1.8 million for Q1 2026, with cash reserves expected to fund operations through Q1 2027.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
